News
TFF Pharmaceuticals Announces Additional Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
15 Apr 24
News
TFF Pharmaceuticals Q4 EPS $(2.01) Beats $(2.12) Estimate, Sales $114.33K Beat $100.00K Estimate
28 Mar 24
Earnings, Earnings Beats, News
Roth MKM Maintains Buy on TFF Pharmaceuticals, Lowers Price Target to $44
28 Mar 24
News, Price Target, Analyst Ratings
12 Health Care Stocks Moving In Wednesday's After-Market Session
27 Mar 24
Movers
TFF Pharmaceuticals Announces Oral Presentation Of Interim Data From The Phase 2 Study Of Tacrolimus Inhalation Powder For The Prevention Of Lung Transplant Rejection At The 44th Annual ISHLT 2024 Meeting
25 Mar 24
Biotech, News, Events, General
TFF Pharmaceuticals Announces Clinical Programs Update And Strategic Prioritization; Company To Prioritize TFF TAC Program Based On Phase 2 Data
20 Mar 24
Biotech, News, General
Press releases
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
27 Mar 24
Press Releases
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
25 Mar 24
News, Health Care, Press Releases
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
22 Mar 24
News, Financing, Press Releases
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
20 Mar 24
Press Releases
TFF Pharmaceuticals Announces Update on Clinical Programs
20 Mar 24
News, Health Care, Press Releases
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
14 Mar 24
News, Press Releases